ABCANN GLOBAL CORPORATION (CVE:ABCN) has appointed Barry Fishman as company’s new Chief Executive Officer, effective October 1, 2017. Fishman has extensive experience of around 20 years as a business leader, recently as CEO of Merus Labs.
Under his leadership, EBITDA and sales surged at a compound annual growth rate of above 50%, ending in the acquisition of Merus by Norgine B.V. in 2017 for around $342 million. Fishman also has experience of serving as a director of public firms in the cannabis sector.
He previously served as CEO of Taro Canada and Teva Canada, and is a past Chairman of the Canadian Generic Manufacturers Association. Fishman commenced his pharmaceutical career at Eli Lilly, where he moved through numerous cross-functional leadership roles.
The management speaks
Ken Clement, the Executive Chairman of ABCANN, reported that Fishman proven experience as a Chief Executive Officer of complex, highly-controlled firms with global operations will serve company and its shareholders well as they continue to follow their growth plan, including the notable expansion of their production capacity, and advancing unique leadership role in the cannabis industry.
Clement added that they would also like to appreciate Aaron Keay for his dedicated and committed work he has done advancing company within the capital markets. They look forward to his sustained active involvement with the firm, including serving on ABCANN Board of Directors. Commenting on his new role, Fishman stated that he is pleased to join company to become part of a team that will continue to lead innovation and advance quality standards in the cannabis market.
Aaron Keay, the CEO and Director of ABcann, expressed that is a thrilling day for everyone linked with company. He is extremely delighted to welcome Fishman to the company as they continue to evolve and improve the leadership within the firm. His experience operating in global markets will be a remarkable addition to ABcann.